SPY330.65-3.85 -1.15%
DIA276.52-2.38 -0.85%
IXIC10,793.28-117.00 -1.07%

UPDATE: Raymond James Upgrades CymaBay Therapeutics To Outperform, Announces $7 Target Notes 'Pending FDA agreement to lift the current clinical hold, seladelpar is back. The development is stunning'

Benzinga · 05/12/2020 16:14